U.S. Insulin Price Rises May Open Way For Biosimilars, Says Novo CEO

The dominant position in the U.S. insulin market enjoyed by Sanofi and Novo Nordisk allowed them to raise prices again recently, but that ability represents a double-edged sword, according to the Danish insulin maker’s CEO, because excessive increases may open the way there for alternative biosimilar products.